Key result
RNA-targeted therapies can suppress SARS-CoV-2 ribosomal frameshifting to inhibit viral translation or promote RNA degradation.
Why the study?
Conformational dynamics, mechanical stability, and structural variability of the viral pseudoknot regulate programmed -1 ribosomal frameshifting, identifying viral RNA structures as potential antiviral targets.
Targeting the conserved SARS-CoV-2 programmed -1 ribosomal frameshifting element with RNA-directed therapeutics represents a promising strategy for next-generation antiviral development.
May support -1 PRF inhibitor development for coronaviruses; leaves open clinical validation in humans.
Programmed -1 ribosomal frameshifting (-1 PRF) is a translational recoding mechanism used by many RNA viruses to regulate the expression of viral replication proteins. In coronaviruses, including SARS-CoV-2, -1 PRF is controlled by a conserved frameshift stimulation element containing a three-stemmed RNA pseudoknot located downstream of a slippery sequence. Studies have shown that conformational dynamics, mechanical stability, and structural variability of the pseudoknot influence ribosome pausing and frameshifting efficiency, identifying viral RNA structures as potential antiviral targets. This review outlines the structural organization, mechanistic basis, and conformational dynamics of viral frameshifting pseudoknots, with emphasis on the SARS-CoV-2 frameshift stimulation element. Advances in cryo-electron microscopy, single-molecule biophysics, molecular dynamics simulations, and computational modeling have identified multiple pseudoknot conformations involved in translational recoding and ribosome-RNA interactions. RNA-targeted therapeutic approaches used to suppress or modulate -1 PRF are also discussed, including small-molecule RNA binders, antisense oligonucleotides, peptide nucleic acids, and ribonuclease-targeting chimeras. These approaches act on distinct aspects of RNA structure, conformational flexibility, and stability to inhibit viral translation or promote selective RNA degradation. Major challenges include selective targeting of highly dynamic RNA structures, optimization of intracellular delivery, and minimizing off-target effects. Integration of structural biology, computational modeling, and RNA-targeted therapeutic strategies may support the development of next-generation antivirals targeting conserved viral RNA regulatory elements.
No takes yet. Share an insight, caveat, or question.
Jeena et al. (2026) conducted a review in SARS-CoV-2. RNA-targeted therapeutic approaches was evaluated. RNA-targeted therapeutic approaches can suppress or modulate SARS-CoV-2 programmed -1 ribosomal frameshifting to inhibit viral translation or promote selective RNA degradation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: